{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:55:00Z","timestamp":1780491300137,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010688","name":"Horizon 2020 European Innovation Council Fast Track to Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.omtm.2022.03.010","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T13:39:52Z","timestamp":1647437992000},"page":"215-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2905-4745","authenticated-orcid":false,"given":"Li-Hsin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens","family":"Liesenborghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanjiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Lox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Bright","family":"Yakass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Lucia","family":"Rosales Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik Jan","family":"Thibaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Teuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Delang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Dallmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2022.03.010_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00134-021-06414-1","article-title":"COVID-19 and the intensive care unit: vaccines to the rescue","volume":"47","author":"Dallmeier","year":"2021","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.omtm.2022.03.010_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00369-6","article-title":"Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action","volume":"6","author":"Heinz","year":"2021","journal-title":"npj Vaccin."},{"key":"10.1016\/j.omtm.2022.03.010_bib3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: the COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J.\u00a0Controlled Release"},{"key":"10.1016\/j.omtm.2022.03.010_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14760584.2020.1711054","article-title":"The potential of adenoviral vaccine vectors with altered antigen presentation capabilities","volume":"19","author":"Neukirch","year":"2020","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.omtm.2022.03.010_bib5","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/S0140-6736(20)32318-7","article-title":"Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination","volume":"396","author":"Anderson","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.omtm.2022.03.010_bib6","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2022.03.010_bib7","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","author":"Cromer","year":"2021","journal-title":"The Lancet Microbe"},{"key":"10.1016\/j.omtm.2022.03.010_bib8","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1016\/j.ymthe.2021.09.024","article-title":"The efficacy of COVID-19 vaccines against the B. 1.617. 2 (delta) variant","volume":"29","author":"Cai","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.03.010_bib9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/14760584.2021.1949293","article-title":"COVID-19 vaccines: concerns beyond protective efficacy and safety","volume":"20","author":"Lai","year":"2021","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.omtm.2022.03.010_bib10","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.ymthe.2021.08.001","article-title":"A comprehensive analysis of the efficacy and safety of COVID-19 vaccines","volume":"29","author":"Cai","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.03.010_bib11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.15585\/mmwr.mm7032e4","article-title":"Use of COVID-19 vaccines after reports of adverse events among adult recipients of janssen (johnson & johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and moderna): update from the advisory committee on immunization practices\u2014United States","volume":"70","author":"Rosenblum","year":"2021","journal-title":"Morbidity Mortality Weekly Rep."},{"key":"10.1016\/j.omtm.2022.03.010_bib12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/14760584.2021.1949294","article-title":"COVID-19 vaccines and thrombosis with thrombocytopenia syndrome","volume":"20","author":"Lai","year":"2021","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.omtm.2022.03.010_bib13","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3390\/vaccines9111326","article-title":"Thrombotic adverse events reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database","volume":"9","author":"Tobaiqy","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.omtm.2022.03.010_bib14","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.03.010_bib15","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after Covid-19 vaccination in a large health care organization","volume":"385","author":"Witberg","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.03.010_bib16","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.4161\/hv.28117","article-title":"The yellow fever 17D virus as a platform for new live attenuated vaccines","volume":"10","author":"Bonaldo","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.omtm.2022.03.010_bib17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","article-title":"A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate","volume":"590","author":"Sanchez-Felipe","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2022.03.010_bib18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3390\/ph14090891","article-title":"The present and future of yellow fever vaccines","volume":"14","author":"Hansen","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omtm.2022.03.010_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vaccine.2014.10.004","article-title":"Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"33","author":"Monath","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.omtm.2022.03.010_bib20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2009.05.018","article-title":"Yellow fever vaccine\u2014how does it work and why do rare cases of serious adverse events take place?","volume":"21","author":"Barrett","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.omtm.2022.03.010_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-19625-9","article-title":"Risk of yellow fever virus transmission in the Asia-Pacific region","volume":"11","author":"de Lataillade","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2022.03.010_bib22","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/527328","article-title":"Substitution of wild-type yellow fever asibi sequences for 17D vaccine sequences in ChimeriVax\u2014dengue 4 does not enhance infection of Aedes aegypti mosquitoes","volume":"197","author":"McGee","year":"2008","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.omtm.2022.03.010_bib23","doi-asserted-by":"crossref","first-page":"e0007299","DOI":"10.1371\/journal.pntd.0007299","article-title":"Midgut barriers prevent the replication and dissemination of the yellow fever vaccine in Aedes aegypti","volume":"13","author":"Danet","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.omtm.2022.03.010_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coviro.2016.03.010","article-title":"Animal models of yellow fever and their application in clinical research","volume":"18","author":"Julander","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.omtm.2022.03.010_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-19684-y","article-title":"STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters","volume":"11","author":"Boudewijns","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2022.03.010_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.virol.2017.04.013","article-title":"Zika virus infection of adult and fetal STAT2 knock-out hamsters","volume":"507","author":"Siddharthan","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2022.03.010_bib27","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.omtm.2022.03.010_bib28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/rmv.1752","article-title":"Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever","volume":"23","author":"Quaresma","year":"2013","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.omtm.2022.03.010_bib29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1128\/JCM.01775-10","article-title":"Detection of yellow fever 17D genome in urine","volume":"49","author":"Domingo","year":"2011","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.omtm.2022.03.010_bib30","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1084\/jem.20182295","article-title":"Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines","volume":"216","author":"Hernandez","year":"2019","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtm.2022.03.010_bib31","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.3390\/v7072795","article-title":"Tissue barriers to arbovirus infection in mosquitoes","volume":"7","author":"Franz","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.omtm.2022.03.010_bib32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.coviro.2015.10.003","article-title":"Dissecting vectorial capacity for mosquito-borne viruses","volume":"15","author":"Kramer","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.omtm.2022.03.010_bib33","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri2629","article-title":"Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology","volume":"9","author":"Pulendran","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtm.2022.03.010_bib34","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1517\/14712598.2012.704908","article-title":"Clinical development of IMOJEV\u00ae\u2014a recombinant Japanese encephalitis chimeric vaccine (JE-CV)","volume":"12","author":"Appaiahgari","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtm.2022.03.010_bib35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/14760584.2017.1335201","article-title":"A recombinant live attenuated tetravalent vaccine for the prevention of dengue","volume":"16","author":"Guy","year":"2017","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.omtm.2022.03.010_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jiq003","article-title":"Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults","volume":"203","author":"Biedenbender","year":"2011","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.omtm.2022.03.010_bib37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/22221751.2020.1730709","article-title":"A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice","volume":"9","author":"Kum","year":"2020","journal-title":"Emerging microbes & infections"},{"key":"10.1016\/j.omtm.2022.03.010_bib38","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1128\/JVI.02255-09","article-title":"Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques","volume":"84","author":"Bonaldo","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2022.03.010_bib39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","article-title":"A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins","volume":"345","author":"Bredenbeek","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2022.03.010_bib40","doi-asserted-by":"crossref","first-page":"100295","DOI":"10.1016\/j.jhepr.2021.100295","article-title":"A novel therapeutic hepatitis B vaccine candidate induces strong polyfunctional cytotoxic T\u00a0cell responses in mice","author":"Boudewijns","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.omtm.2022.03.010_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.omtm.2022.03.010_bib42","doi-asserted-by":"crossref","first-page":"taw045","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007\u201313","volume":"23","author":"Lindsey","year":"2016","journal-title":"J.\u00a0Trav. Med."},{"key":"10.1016\/j.omtm.2022.03.010_bib43","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1016\/j.vaccine.2020.06.008","article-title":"Adverse events following immunization with the live-attenuated recombinant Japanese encephalitis vaccine (IMOJEV\u00ae) in Taiwan, 2017\u201318","volume":"38","author":"Ma","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.omtm.2022.03.010_bib44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","article-title":"The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review","volume":"86","author":"Thomas","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.omtm.2022.03.010_bib45","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1016\/j.vaccine.2013.09.030","article-title":"Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review","volume":"31","author":"Rafferty","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.omtm.2022.03.010_bib46","doi-asserted-by":"crossref","first-page":"e20202486","DOI":"10.1084\/jem.20202486","article-title":"Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine","volume":"218","author":"Bastard","year":"2021","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtm.2022.03.010_bib47","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-stimulated genes: what do they all do?","volume":"6","author":"Schoggins","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omtm.2022.03.010_bib48","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1016\/j.vaccine.2010.10.070","article-title":"WHO Working Group on technical specifications for manufacture and evaluation of yellow fever vaccines","volume":"28","author":"Ferguson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.omtm.2022.03.010_bib49","doi-asserted-by":"crossref","first-page":"e109755","DOI":"10.1371\/journal.pone.0109755","article-title":"Efficient gene targeting in golden Syrian hamsters by the CRISPR\/Cas9 system","volume":"9","author":"Fan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2022.03.010_bib50","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1080\/22221751.2019.1694394","article-title":"Limited evolution of the yellow fever virus 17d in a mouse infection model","volume":"8","author":"Kum","year":"2019","journal-title":"Emerging Microbes Infections"},{"key":"10.1016\/j.omtm.2022.03.010_bib51","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4269\/ajtmh.1999.60.292","article-title":"Variation in oral susceptibility to dengue type 2 virus of populations of Aedes aegypti from the islands of Tahiti and Moorea, French Polynesia","volume":"60","author":"Vazeille-Falcoz","year":"1999","journal-title":"Am. J. Trop. Med. Hyg."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122000407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122000407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:30:02Z","timestamp":1762421402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050122000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":51,"alternative-id":["S2329050122000407"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2022.03.010","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.24.477505","asserted-by":"object"}]},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2022.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}]}}